文摘
摘要目的:评估疾病特征在非洲、加勒比和黑色pwm (ACB-MS)随后在圣迈克尔医院在多伦多,加拿大。
背景:异质性在多发性硬化症患者之间的临床过程(pwm)已经被观察到的种族和族裔群体之间。在美国,一致的数据表明,黑人或非裔美国人(AA) pwm有更大的疾病严重程度而非/ non-AA人。
设计/方法:ACB-MS比较随着年龄的增长,sex-matched欧洲血统的pwm (EUR-MS)女士诊所注册表来确定的。疾病活动和严重程度进行评估使用年复发率(ARR),扩大残疾状态量表(eds)评分,严重度评分(mss)女士和发展指数(PI)。
结果:344例(n = 172 ACB-MS;n = 172 EUR-MS;平均年龄43岁,68%女性)是包括在内。女士发病的平均年龄是29年,平均疾病持续时间是14年人口。复发缓和多发性硬化症(名RRMS)是最常见的疾病亚型(分别为74%和71%的ACB-MS和EUR-MS)。疾病的临床和放射学措施活动通常是类似ACB-MS和EUR-MS之间,包括加勒比海盗(0.47±0.47和0.41±0.34,p = 0.2),最近eds得分(中位数2.0两组,p = 0.10),和比例的核磁共振成像新/扩大T2病灶(25%恶化在两组,p = 0.76)。残疾发展随着时间的推移在ACB-MS vs EUR-MS更大(43%比33%,p = 0.04),但疾病严重程度的措施,包括海量存储系统(mss)中(ACB-MS 3.17 vs EUR-MS 2.58, p = 0.3)和π(ACB-MS 0.27 vs EUR-MS 0.30, p = 0.5)是相同的。之间没有区别人群对“疗效”疗法使用(natalizumab,阿仑单抗、ocrelizumab cladribine, fingolimod)在最近的访问(p = 0.8)。
结论:女士疾病活动和严重程度通常是类似ACB-MS与EUR-MS病人在多伦多,加拿大。这些发现与之前的研究证明高女士黑色和AA女士人群的疾病严重程度。不同的环境、遗传、表观遗传和获得医疗保健可能解释这个观察到的差异,并进一步研究是必要的。
披露:Kuczynski博士没有披露。阿什利·琼斯没有披露。Muccilli博士没有披露。Selchen博士已经收到个人赔偿范围在10000 - 49999美元的EMD Serono演讲人。Selchen博士已经收到个人薪酬在5000 - 9999美元的范围在罗氏的演讲人。Selchen博士已经收到个人薪酬在5000 - 9999美元的范围在诺华的演讲人。Selchen博士已经收到个人薪酬在10000 - 49999美元的范围为Teva作为专家证人。奥田硕博士已经收到个人薪酬在500 - 4999美元的范围为Alexion担任顾问。奥田硕博士已经收到个人薪酬在500 - 4999美元的范围作为顾问生原体。奥田硕博士已经收到个人薪酬在5000 - 9999美元的范围为Celgene公司担任顾问。 Dr. Okuda has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genzyme. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for VielaBio. Stefan Baral has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. The institution of Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD-Serono. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Oh has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Oh has received research support from Biogen-Idec. The institution of Dr. Oh has received research support from EMD-Serono. The institution of Dr. Oh has received research support from Biogen-Idec.
